Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
In this episode of Speaking of Urology®, Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 American Urological Association Annual Meeting, which was held April 28-May 1 in Chicago, Illinois. Badlani is a Urology Times coeditor in chief and professor and vice chair of urology at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and Dr. Kaplan is a professor of Urology and a director of the men’s wellness program at the Icahn School of Medicine at Mount Sinai in New York.
During their discussion, they touched on the following topics:
Don’t forget to subscribe to Speaking of Urology® on Spotify, Apple Podcasts, or anywhere that podcasts are available.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.